AFFILIATIONS
1 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
2 Capital Medical University Affiliated Beijing Friendship Hospital, Beijing, China
3 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
4 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
5 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
6 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
7 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
8 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
9 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
10 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
11 Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, Beijing, China
ABSTRACT
Objective: To investigate the efficacy and safety of complement inhibitors (CIs) combined with cyclosporine A (CsA) and thrombopoietin receptor agonists (TPO-RAs) in the treatment of patients with paroxysmal nocturnal hemoglobinuria concurrent with aplastic anemia (AA/PNH). Method: Data were retrospectively collected from 65 patients with AA/PNH at Peking Union Medical College Hospital between December 2022 and June 2025. All patients received regular CI therapy combined with full-dose CsA and TPO-RAs, with a follow-up of ≥ 6 months. Hemolysis, AA control, and adverse events were evaluated. Result: A total of 65 patients were included, with a median age at PNH diagnosis of 40 (18–79) years and a male proportion of 53.8% (35/65). 39 patients (60.0%) received eculizumab and 26 (40.0%) received iptacopan. All patients were treated with CsA combination of eltrombopag. The median treatment duration was 6 (6–36) months, and the median follow-up was 10 (6–36) months. At 1, 3, 6 months and at last follow-up, the overall response rates (ORR) were 84.6% (55/65), 89.2% (58/65), 93.8% (61/65), and 95.4% (62/65), respectively, whereas the complete response rates (CRR) were 0% (0/65), 12.3% (8/65), 18.5% (12/65), and 21.5% (14/65), respectively. At last follow-up, 89.2% (58/65) of patients achieved lactate dehydrogenase (LDH) < 1.5 × ULN and 56.9% (37/65) achieved LDH < 1.0 × ULN. Adverse events were mild and reversable. Propensity-matched subgroup analysis demonstrated that iptacopan was superior to eculizumab in improving LDH, hemoglobin(HGB), reticulocyte count, total bilirubin, and was associated with a lower incidence of breakthrough hemolysis (BTH) (all P < 0.05). Conclusion: The combination therapy of CI with CsA and TPO-RAs effectively ameliorates hemolysis and AA in patients with AA/PNH, demonstrating a favorable safety profile. Iptacopan exhibits superior hemolysis control compared with eculizumab in the short term.
DISCLOSURES
Qilin Zhuang, Student at Peking Union Medical College: No relevant conflicts of interest to declare.